AU6143694A - Use of 2h-1,2,4-benzothiadiazine 3(4h)-one 1,1 dioxide derivatives as non-competitive nmda receptor antagonists - Google Patents

Use of 2h-1,2,4-benzothiadiazine 3(4h)-one 1,1 dioxide derivatives as non-competitive nmda receptor antagonists

Info

Publication number
AU6143694A
AU6143694A AU61436/94A AU6143694A AU6143694A AU 6143694 A AU6143694 A AU 6143694A AU 61436/94 A AU61436/94 A AU 61436/94A AU 6143694 A AU6143694 A AU 6143694A AU 6143694 A AU6143694 A AU 6143694A
Authority
AU
Australia
Prior art keywords
benzothiadiazine
receptor antagonists
nmda receptor
dioxide derivatives
competitive nmda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61436/94A
Inventor
Francois Audiau
Patrick Jimonet
Serge Mignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU6143694A publication Critical patent/AU6143694A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AU61436/94A 1993-03-03 1994-02-25 Use of 2h-1,2,4-benzothiadiazine 3(4h)-one 1,1 dioxide derivatives as non-competitive nmda receptor antagonists Abandoned AU6143694A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9302439A FR2702150B1 (en) 1993-03-03 1993-03-03 Application of 2H-1,2-4-benzothiadiazine-3 (4H) -one-1,1-dioxide derivatives as non-competitive NMDA receptor antagonists.
FR9302439 1993-03-03
PCT/FR1994/000207 WO1994020109A1 (en) 1993-03-03 1994-02-25 Use of 2h-1,2,4-benzothiadiazine 3(4h)-one 1,1 dioxide derivatives as non-competitive nmda receptor antagonists

Publications (1)

Publication Number Publication Date
AU6143694A true AU6143694A (en) 1994-09-26

Family

ID=9444603

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61436/94A Abandoned AU6143694A (en) 1993-03-03 1994-02-25 Use of 2h-1,2,4-benzothiadiazine 3(4h)-one 1,1 dioxide derivatives as non-competitive nmda receptor antagonists

Country Status (10)

Country Link
EP (1) EP0687178A1 (en)
JP (1) JPH08507303A (en)
AU (1) AU6143694A (en)
CA (1) CA2153951A1 (en)
FR (1) FR2702150B1 (en)
HU (1) HU9502572D0 (en)
IL (1) IL108784A0 (en)
NO (1) NO953387L (en)
PL (1) PL310439A1 (en)
WO (1) WO1994020109A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975925A (en) * 1961-02-21 1964-11-25 Scherico Ltd 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides
US4716161A (en) * 1984-04-17 1987-12-29 Mitsubishi Chemical Industries Limited Phenylpiperazine derivatives and their acid addition salts
FR2675801A1 (en) * 1991-04-24 1992-10-30 Rhone Poulenc Rorer Sa Piperidines, their preparation and the medicaments containing them
FR2690160A1 (en) * 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application of 2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxylic acid derivatives to the preparation of medicaments, new products, their preparation and the medicaments containing them.
AU3957093A (en) * 1992-04-15 1993-11-18 Rhone-Poulenc Rorer S.A. 3,4-dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxyl ic acid derivatives, preparation thereof and drugs containing same

Also Published As

Publication number Publication date
PL310439A1 (en) 1995-12-11
FR2702150B1 (en) 1995-04-07
EP0687178A1 (en) 1995-12-20
WO1994020109A1 (en) 1994-09-15
CA2153951A1 (en) 1994-09-15
JPH08507303A (en) 1996-08-06
NO953387D0 (en) 1995-08-29
IL108784A0 (en) 1994-06-24
FR2702150A1 (en) 1994-09-09
HU9502572D0 (en) 1995-11-28
NO953387L (en) 1995-08-29

Similar Documents

Publication Publication Date Title
HUP9902056A3 (en) Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
HUP0003999A3 (en) Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them
SG47877A1 (en) Use of tetrahydrocarbazone derivatives as 5HT receptor agonists
HUP0104646A3 (en) Fused 1,2,4-thiadiazine derivatives, their preparation and use
EP0442878A4 (en) Derivatives of tryptophan as cck antagonists
PH30439A (en) 3,4-Dihydro-2h-1,4-benz-oxazine derivatives and pharmaceutical compositions containing the same
EP0707581A1 (en) Indoline derivatives as 5ht 2c? antagonists
AU6143694A (en) Use of 2h-1,2,4-benzothiadiazine 3(4h)-one 1,1 dioxide derivatives as non-competitive nmda receptor antagonists
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
HUP9904032A3 (en) 1,2,4-benzothiadiazine derivatives,their preparation and use
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
AU6524996A (en) Piperazine derivatives and their use as 5-HT1A antagonists
AU3421493A (en) Use of spiperone or spiperone derivatives as immunosuppressant agents
AU9068398A (en) 3-substituted 3,4,5,7-tetrahydro-pyrrolo3',4':4,5 thieno2,3-dpyrimidine derivatives, their preparation and use as 5ht antagonists
HUP0003689A3 (en) Benzothiazine dioxide derivatives with endothelin antagonist activity, pharmaceutical compositions containing them and process for the preparation of known derivatives
DK0880522T3 (en) 5H, 10H-Imidazo [1,2-a] indeno [1,2-e] pyrazin-4-one derivatives AMPA and NMDA receptor antagonists, their preparation, their intermediates and drugs containing them
AU1054500A (en) N-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives, their preparation and their use as selective mglur1 antagonists
AU3957193A (en) Use of 2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxylic acid derivatives for preparing NMDA/AMPA receptor antagonist drugs, novel products, preparation thereof and drugs containing same
AU4282993A (en) Benzothiazepine and benzoxazepine derivatives as cholecystokinin receptor antagonists
AU3769089A (en) Alpha-adrenergic receptor antagonists
AU1663399A (en) Pyrido 1,2,4-thiadiazine derivatives, their preparation and use
GB2270313B (en) 1,3,4-Benzotriazepin-5 (4H)-one derivatives and process for the preparation thereof
AU1555999A (en) 1,2,4-benzothiadiazine derivatives, their preparation and use
IL104119A (en) 3-substituted (optionally)-5,5-disubstituted-4-oxo-thiazolidin-2-yliden-1-amino-3-substituted-imidazolidin-2- thion-4- or 5-one or 4,5-dione derivatives their preparation and pharmaceutical compositions comprising them
AU7660194A (en) 3,4-dihydro-2h-1,2,4-benzothiadiazine 1,1-dioxide-3-carboxylic acid derivatives, their preparation and drugs containing same